// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Eltrombopag for the treatment of congenital thrombocytopenia: successful response in 2 cousins with identical gene abnormality

A Darbyshire - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Eltrombopag

High incidence of fractures during and after treatment in children with acute lymphoblastic leukaemia

BLS Ho - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Methotrexate

Management of congenital thrombotic thrombocytopenic purpura using BPL Factor 8Y; a single centre report

A Akinsete - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

FVIII

Incidence of vertebral abnormalities at presentation in children with acute lymphoblastic leukaemia

BLS Ho - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Management of chronic ITP with Rituximab and TPO (Thrombopoietin)‐mimetics

Y Gupta - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

N/A

Mycophenolate mofetil

Neurocognitive deficits in sickle cell disease: links with nocturnal oxygen desaturation in adolescents, but not children

H Stotesbury - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

N/A

N/A

Neonatal blood transfusion at Imperial College Healthcare Trust

K Orf - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Nursing knowledge about lymphoma: how nurses working on a Haematology Day Unit in Cardiff want their education provided

R Harries - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

How should holistic support services be presented to patients in a Chemotherapy Day Unit situation: an audit of what lymphoma patients in Cardiff want

R Harries - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Whole body magnetic resonance imaging (WB‐MRI) is more sensitive than 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG PET/CT) for baseline assessment of myeloma bone disease

I El-Najjar - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Evaluating the use of multi‐parametric flow cytometry in the assessment of minimal residual disease and treatment response following autologous stem cell transplant in patients with myeloma

S Khanna - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Lanthanum carbonate

Experience of pomalidomide use in refractory and relapsed multiple myeloma within Glasgow, UK

M Rafferty - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Dexamethasone

Whole body magnetic resonance imaging (WB‐MRI) assessment of myeloma: do additional diffusion weighted and post contrast T1 DIXON sequences add diagnostic value?

S Natas - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Symptomatic skeletal lesions: a previously unreported manifestation of Waldenström's macroglobulinaemia, which can represent disease progression

A O'Neill - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Methylprednisolone

Clinical profile of long responders (>36 months) to lenalidomide based therapy in multiple myeloma in a single centre

M Joffe - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Lenalidomide

Apixaban for thromboprophylaxis in myeloma treated with immunomodulatory therapy appears to be safe and effective

N Storrar - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

apixaban

Duration of therapy is independently associated with improved progression free and overall survival following first line therapy in non‐transplant eligible patients with multiple myeloma: real‐life experience from a UK centre

D De-Silva - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bortezomib

Diffusion weighted whole body magnetic resonance imaging is superior to skeletal survey for baseline assessment of myeloma bone disease

M Streetly - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Total dose but not combination of Bortezomib regimen influences outcomes in multiple myeloma

A Srinivasan - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Bortezomib

Cancer network level analysis of clinical outcomes in transplant eligible NDMM patients

F Djebbari - British Society for Hematology (BSH) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved